Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J, Friedlander SF, Cribier B, Morren MA, García-Díez A, Gelmetti C, Hofmann H, Houwing RH, Kownacki S, Langley RG, Virtanen M, Wolff K, Wisseh S, McGeown C, Abrams B, Schneider D; NOBEL (New Online Based ELidel) Study Group. Lübbe J, et al. Among authors: schneider d. Am J Clin Dermatol. 2006;7(2):121-31. doi: 10.2165/00128071-200607020-00005. Am J Clin Dermatol. 2006. PMID: 16605292 Clinical Trial.
Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M, Steinhoff M, Schneider D, Luger TA. Grassberger M, et al. Among authors: schneider d. Exp Dermatol. 2004 Dec;13(12):721-30. doi: 10.1111/j.0906-6705.2004.00269.x. Exp Dermatol. 2004. PMID: 15560755 Review.
Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort.
Simon D, Lübbe J, Wüthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schöni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobalj N, Schneider D. Simon D, et al. Among authors: schneider d. Dermatology. 2006;213(4):313-8. doi: 10.1159/000096195. Dermatology. 2006. PMID: 17135737 Free article. Clinical Trial.
[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C, Weiss JM, Bextermöller R, Löffler H, Schneider D. Sunderkötter C, et al. Among authors: schneider d. J Dtsch Dermatol Ges. 2006 Apr;4(4):301-6. doi: 10.1111/j.1610-0387.2006.05932.x. J Dtsch Dermatol Ges. 2006. PMID: 16638059 Clinical Trial. German.
Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J, Abraham A, de Cuyper C, Kim K, Langeland T, Parra V, Pigatto P, Reunala T, Szczepanski R, Möhrenschlager M, Bräutigam M, Rossi AB, Meents-Kopecky E, Schneider D. Ring J, et al. Among authors: schneider d. J Eur Acad Dermatol Venereol. 2008 Feb;22(2):195-203. doi: 10.1111/j.1468-3083.2007.02368.x. J Eur Acad Dermatol Venereol. 2008. PMID: 18211413 Clinical Trial.
3,276 results